Table 1 Patient characteristics of MS patients and controls

From: PD-L1 positive astrocytes attenuate inflammatory functions of PD-1 positive microglia in models of autoimmune neuroinflammation

Cohorts (n)

Females (%)

Age (years)

Disease duration (years)

EDSS

Treatment

Fig. 1

     

 Controls (44)

31 (70.5%)

37.1 [26.5: 48.3]

None

None

None

 CIS (21)

16 (76.2%)

33.4 [27.1: 37.2]

None

1.4 [0.5: 2.0]

None

 RRMS relapse (53)

36 (67.9%)

33.2 [27.6: 38.5]

2.3 [0.0: 3.0]

1.9 [1.0: 3.0]

None

 SPMS (12)

19 (50.0%)

55.3 [51.6: 63.1]

14.2 [8.3: 17.0]

5.2 [4.0: 6.9]

3 (25.0%)

 PPMS (14)

6 (42.9%)

47.2 [44.5: 54.8]

4.8 [1.0: 6.5]

4.0 [2.9: 4.5]

1 (7.1%)

Fig. 2

 CIS (17)

13 (76.5%)

34.1 [29.5: 37.0]

None

1.4 [1.0: 2.0]

None

  1. Clinical information of patients used for the analysis of soluble PD-L1 in the cerebrospinal fluid and AhR activity by luciferase assay.